Article
Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates
11 Oct 2019
Abstract excerpt
Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have promising utility in prevention and treatment of HIV-1 infection, and several are currently undergoing clinical trials. Due to the high sequence diversity and mutation rate of HIV-1, viral isolates are often resistant to specific bNAbs. Currently, resistant isolates are commonly identified by time-consuming and expensive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
